Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans

Robert Shangraw, R. Winter, J. Hromco, Stephen Robinson, E. J. Gallaher

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Marked lactic acidosis occurs during orthotopic liver transplantation (OLT), especially during the anhepatic phase. Current standard therapy is NaHCO3, although it may exacerbate intracellular acidosis, increase plasma lactate, and contribute to hypernatremia. Alternatively, dichloroacetate (DCA) stimulates pyruvate oxidation in vivo, reduces plasma lactate, and moderates intracellular acidosis. The aims of this study were to test the efficacy of DCA to control lactic acidosis, reduce the NaHCO3 requirement and incidence of hypernatremia, and stabilize perioperative acid-base homeostasis. Others aims were to examine the DCA pharmacokinetic profile during OLT and the role of lactate metabolism in OLT- associated hyperglycemia. Methods: Patients (n = 66) for OLT were divided into two equal groups to receive or not receive DCA during OLT. DCA 40 mg · kg-1 was infused over 60 min after induction of anesthesia and 4 h later. Plasma DCA concentration was measured by gas chromatography-mass spectroscopy, and pharmacokinetics were assessed by a one-compartment model. Serial arterial blood gases, lactate, Na+, glucose, and hemodynamic measurements were compared, as were intraoperative utilization of blood products, CaCl2, and NaHCO3. Results: Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 ± 0.06 (mean ± SE) and 1.18 ± 0.09 mM, respectively after the first and second doses. In control patients, plasma lactate was 1.07 ± 0.04 at baseline and 1.20 ± 0.06 before incision and reached a peak of 7.30 ± 0.41 mM after graft reperfusion. In DCA-treated patients, the respective values were 1.07 ± 0.06 (difference not significant), 0.63 ± 0.05 (P <0.001), and 3.39 ± 0.20 (P <0.001) mM. Intraoperative changes in arterial blood pH, HCO3 -1, and base excess were comparable though less marked in DCA-treated patients, whose NaHCO3 requirement was reduced (0.59 ± 0.36 vs. 2.83 ± 0.53 mEq · kg-1 in control patients, P <0.001). There was no difference between groups in requirements for CaCl2 or blood products, in intraoperative hemodynamics, in duration of the surgical stages, or in graft ischemia times. Twelve control and 4 DCA-treated patients exhibited a plasma Na+ concentration > 145 mEq/l at completion of surgery (P <0.05). Hyperglycemia was not attenuated by DCA despite decreased plasma lactate concentration. Sixteen and 28 h after graft reperfusion, when plasma DCA had been eliminated, plasma lactate and degree of metabolic alkalosis did not differ between groups. Conclusions: DCA safely and effectively attenuated lactic acid accumulation and moderated acidosis during OLT. DCA decreased the requirement for NaHCO3 therapy and the incidence of hypernatremia. OLT- associated hyperglycemia did not result from lactate-induced stimulation of hepatic gluconeogenesis. Postoperative metabolic alkalosis was not substantially influenced by lactate metabolism.

Original languageEnglish (US)
Pages (from-to)1127-1138
Number of pages12
JournalAnesthesiology
Volume81
Issue number5
StatePublished - 1994

Fingerprint

Lactic Acidosis
Liver Transplantation
Lactic Acid
Hypernatremia
Acidosis
Hyperglycemia
Alkalosis
Reperfusion
Pharmacokinetics
Transplants
Gluconeogenesis
Incidence
Pyruvic Acid
Gas Chromatography
Mass Spectrometry
Homeostasis
Anesthesia
Gases
Hemodynamics
Glucose

Keywords

  • Acid-base equilibrium: bicarbonate; dichloroacetate
  • Metabolism: glucose; lactate; sodium
  • Transplantation: liver

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. / Shangraw, Robert; Winter, R.; Hromco, J.; Robinson, Stephen; Gallaher, E. J.

In: Anesthesiology, Vol. 81, No. 5, 1994, p. 1127-1138.

Research output: Contribution to journalArticle

@article{420aea9465ff41f3bc679eac3494f9bb,
title = "Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans",
abstract = "Background: Marked lactic acidosis occurs during orthotopic liver transplantation (OLT), especially during the anhepatic phase. Current standard therapy is NaHCO3, although it may exacerbate intracellular acidosis, increase plasma lactate, and contribute to hypernatremia. Alternatively, dichloroacetate (DCA) stimulates pyruvate oxidation in vivo, reduces plasma lactate, and moderates intracellular acidosis. The aims of this study were to test the efficacy of DCA to control lactic acidosis, reduce the NaHCO3 requirement and incidence of hypernatremia, and stabilize perioperative acid-base homeostasis. Others aims were to examine the DCA pharmacokinetic profile during OLT and the role of lactate metabolism in OLT- associated hyperglycemia. Methods: Patients (n = 66) for OLT were divided into two equal groups to receive or not receive DCA during OLT. DCA 40 mg · kg-1 was infused over 60 min after induction of anesthesia and 4 h later. Plasma DCA concentration was measured by gas chromatography-mass spectroscopy, and pharmacokinetics were assessed by a one-compartment model. Serial arterial blood gases, lactate, Na+, glucose, and hemodynamic measurements were compared, as were intraoperative utilization of blood products, CaCl2, and NaHCO3. Results: Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 ± 0.06 (mean ± SE) and 1.18 ± 0.09 mM, respectively after the first and second doses. In control patients, plasma lactate was 1.07 ± 0.04 at baseline and 1.20 ± 0.06 before incision and reached a peak of 7.30 ± 0.41 mM after graft reperfusion. In DCA-treated patients, the respective values were 1.07 ± 0.06 (difference not significant), 0.63 ± 0.05 (P <0.001), and 3.39 ± 0.20 (P <0.001) mM. Intraoperative changes in arterial blood pH, HCO3 -1, and base excess were comparable though less marked in DCA-treated patients, whose NaHCO3 requirement was reduced (0.59 ± 0.36 vs. 2.83 ± 0.53 mEq · kg-1 in control patients, P <0.001). There was no difference between groups in requirements for CaCl2 or blood products, in intraoperative hemodynamics, in duration of the surgical stages, or in graft ischemia times. Twelve control and 4 DCA-treated patients exhibited a plasma Na+ concentration > 145 mEq/l at completion of surgery (P <0.05). Hyperglycemia was not attenuated by DCA despite decreased plasma lactate concentration. Sixteen and 28 h after graft reperfusion, when plasma DCA had been eliminated, plasma lactate and degree of metabolic alkalosis did not differ between groups. Conclusions: DCA safely and effectively attenuated lactic acid accumulation and moderated acidosis during OLT. DCA decreased the requirement for NaHCO3 therapy and the incidence of hypernatremia. OLT- associated hyperglycemia did not result from lactate-induced stimulation of hepatic gluconeogenesis. Postoperative metabolic alkalosis was not substantially influenced by lactate metabolism.",
keywords = "Acid-base equilibrium: bicarbonate; dichloroacetate, Metabolism: glucose; lactate; sodium, Transplantation: liver",
author = "Robert Shangraw and R. Winter and J. Hromco and Stephen Robinson and Gallaher, {E. J.}",
year = "1994",
language = "English (US)",
volume = "81",
pages = "1127--1138",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans

AU - Shangraw, Robert

AU - Winter, R.

AU - Hromco, J.

AU - Robinson, Stephen

AU - Gallaher, E. J.

PY - 1994

Y1 - 1994

N2 - Background: Marked lactic acidosis occurs during orthotopic liver transplantation (OLT), especially during the anhepatic phase. Current standard therapy is NaHCO3, although it may exacerbate intracellular acidosis, increase plasma lactate, and contribute to hypernatremia. Alternatively, dichloroacetate (DCA) stimulates pyruvate oxidation in vivo, reduces plasma lactate, and moderates intracellular acidosis. The aims of this study were to test the efficacy of DCA to control lactic acidosis, reduce the NaHCO3 requirement and incidence of hypernatremia, and stabilize perioperative acid-base homeostasis. Others aims were to examine the DCA pharmacokinetic profile during OLT and the role of lactate metabolism in OLT- associated hyperglycemia. Methods: Patients (n = 66) for OLT were divided into two equal groups to receive or not receive DCA during OLT. DCA 40 mg · kg-1 was infused over 60 min after induction of anesthesia and 4 h later. Plasma DCA concentration was measured by gas chromatography-mass spectroscopy, and pharmacokinetics were assessed by a one-compartment model. Serial arterial blood gases, lactate, Na+, glucose, and hemodynamic measurements were compared, as were intraoperative utilization of blood products, CaCl2, and NaHCO3. Results: Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 ± 0.06 (mean ± SE) and 1.18 ± 0.09 mM, respectively after the first and second doses. In control patients, plasma lactate was 1.07 ± 0.04 at baseline and 1.20 ± 0.06 before incision and reached a peak of 7.30 ± 0.41 mM after graft reperfusion. In DCA-treated patients, the respective values were 1.07 ± 0.06 (difference not significant), 0.63 ± 0.05 (P <0.001), and 3.39 ± 0.20 (P <0.001) mM. Intraoperative changes in arterial blood pH, HCO3 -1, and base excess were comparable though less marked in DCA-treated patients, whose NaHCO3 requirement was reduced (0.59 ± 0.36 vs. 2.83 ± 0.53 mEq · kg-1 in control patients, P <0.001). There was no difference between groups in requirements for CaCl2 or blood products, in intraoperative hemodynamics, in duration of the surgical stages, or in graft ischemia times. Twelve control and 4 DCA-treated patients exhibited a plasma Na+ concentration > 145 mEq/l at completion of surgery (P <0.05). Hyperglycemia was not attenuated by DCA despite decreased plasma lactate concentration. Sixteen and 28 h after graft reperfusion, when plasma DCA had been eliminated, plasma lactate and degree of metabolic alkalosis did not differ between groups. Conclusions: DCA safely and effectively attenuated lactic acid accumulation and moderated acidosis during OLT. DCA decreased the requirement for NaHCO3 therapy and the incidence of hypernatremia. OLT- associated hyperglycemia did not result from lactate-induced stimulation of hepatic gluconeogenesis. Postoperative metabolic alkalosis was not substantially influenced by lactate metabolism.

AB - Background: Marked lactic acidosis occurs during orthotopic liver transplantation (OLT), especially during the anhepatic phase. Current standard therapy is NaHCO3, although it may exacerbate intracellular acidosis, increase plasma lactate, and contribute to hypernatremia. Alternatively, dichloroacetate (DCA) stimulates pyruvate oxidation in vivo, reduces plasma lactate, and moderates intracellular acidosis. The aims of this study were to test the efficacy of DCA to control lactic acidosis, reduce the NaHCO3 requirement and incidence of hypernatremia, and stabilize perioperative acid-base homeostasis. Others aims were to examine the DCA pharmacokinetic profile during OLT and the role of lactate metabolism in OLT- associated hyperglycemia. Methods: Patients (n = 66) for OLT were divided into two equal groups to receive or not receive DCA during OLT. DCA 40 mg · kg-1 was infused over 60 min after induction of anesthesia and 4 h later. Plasma DCA concentration was measured by gas chromatography-mass spectroscopy, and pharmacokinetics were assessed by a one-compartment model. Serial arterial blood gases, lactate, Na+, glucose, and hemodynamic measurements were compared, as were intraoperative utilization of blood products, CaCl2, and NaHCO3. Results: Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 ± 0.06 (mean ± SE) and 1.18 ± 0.09 mM, respectively after the first and second doses. In control patients, plasma lactate was 1.07 ± 0.04 at baseline and 1.20 ± 0.06 before incision and reached a peak of 7.30 ± 0.41 mM after graft reperfusion. In DCA-treated patients, the respective values were 1.07 ± 0.06 (difference not significant), 0.63 ± 0.05 (P <0.001), and 3.39 ± 0.20 (P <0.001) mM. Intraoperative changes in arterial blood pH, HCO3 -1, and base excess were comparable though less marked in DCA-treated patients, whose NaHCO3 requirement was reduced (0.59 ± 0.36 vs. 2.83 ± 0.53 mEq · kg-1 in control patients, P <0.001). There was no difference between groups in requirements for CaCl2 or blood products, in intraoperative hemodynamics, in duration of the surgical stages, or in graft ischemia times. Twelve control and 4 DCA-treated patients exhibited a plasma Na+ concentration > 145 mEq/l at completion of surgery (P <0.05). Hyperglycemia was not attenuated by DCA despite decreased plasma lactate concentration. Sixteen and 28 h after graft reperfusion, when plasma DCA had been eliminated, plasma lactate and degree of metabolic alkalosis did not differ between groups. Conclusions: DCA safely and effectively attenuated lactic acid accumulation and moderated acidosis during OLT. DCA decreased the requirement for NaHCO3 therapy and the incidence of hypernatremia. OLT- associated hyperglycemia did not result from lactate-induced stimulation of hepatic gluconeogenesis. Postoperative metabolic alkalosis was not substantially influenced by lactate metabolism.

KW - Acid-base equilibrium: bicarbonate; dichloroacetate

KW - Metabolism: glucose; lactate; sodium

KW - Transplantation: liver

UR - http://www.scopus.com/inward/record.url?scp=0028139290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028139290&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 1127

EP - 1138

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 5

ER -